Comparison of the efficacy of solifenacin and duloxetine in the treatment of overactive bladder disease

Comparative study of the efficacy of solifenacin with duloxetine in the treatment of overactive bladder disease in women

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191010045047N1

Enrollment

Registered

2019-12-19

Start date

2019-10-17

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

over active bladder. other specified disorders of bladder

Interventions

Intervention 1: intervention Group 1: 10mg daily anti-cholinergic solifenacin drug made by abidi Pharmaceutical Company for a month. Intervention 2: Intervention group2: Serotonin norepinephrine reupt

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All women had urinary frequency more than six times a day at intervals less than one hour

Exclusion criteria

Exclusion criteria: urinary tract infection diabetes under 18 years old BMI greater than 35 smokers having bladder stones previous surgical history

Design outcomes

Primary

Measure	Time frame
Patients symptoms of OAB. Timepoint: First of trial and one month later. Method of measurement: International consultation on incontinence questionnaire.;Drug side effects. Timepoint: One month later. Method of measurement: Patient history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahbobe mirzaei

Kerman University of Medical Sciences

mirzaeimahboubeh@yahoo.com+98 34 3222 1600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026